Ocata Therapeutics Inc fka OCAT

[rocky301]

ACTC BOD Erkki Ruoslahti,

BioTime+Ruoslahti

"The acquired technology includes technology patented by CTI and an exclusive license to use technology invented by Dr. Erkki Ruoslahti's group at the Sanford-Burnham Medical Research Institute (SBMRI) for use in cell therapy."
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=43194&GoTopage=1&Category=1802&BzID=1152

The Ruoslahti laboratory in Santa Barbara is a branch of Sanford-Burnham Medical Research Institute affiliated with UCSB

The underlying themes of Dr. Ruoslahti’s work are tumor vasculature and metastasis. Tumors, like other tissues, contain both blood vessels and lymphatic vessels. A tumor needs blood vessels to be able to grow, and destroying tumor blood vessels is the basis of a promising new cancer therapy. Lymphatic vessels are not needed for tumor growth, but like blood vessels, the lymphatics are an important conduit of distant metastasis.
http://www.sanfordburnham.org/research_and_faculty/faculty_search/ruoslahti_e_md_phd.aspx